Two new vaccines for respiratory syncytial virus (RSV) are available this year for people aged 60 and older, as well as for those between 32 and 36 weeks pregnant. These vaccines-Arexvy by GSK and ...
GSK has received approval from Japan’s MHLW for RSV vaccine Arexvy to prevent RSV disease in adults aged over 60 years ...
Women may soon have a vaccine they can take during a pregnancy to help protect their newborn from respiratory syncytial virus ...
GSK plc has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for its Arexvy (respiratory ...
Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, that can help to protect infants through the active immunisation ...
New Scientist explains how the latest covid-19 booster vaccines are different from previous ones, and who should get them ...
The way has been largely cleared for the rollout of Pfizer’s respiratory syncytial virus (RSV) vaccine to help protect ...
The shot will help shield newborns from RSV in the early months of life, when they're especially vulnerable to severe illness ...
U.S. health officials are recommending RSV vaccinations for moms-to-be as a second option to protect newborns. The Centers ...
Health Minister Stephen Donnelly will update the Cabinet this morning about plans to deal with viruses circulating this ...
GSK plc (GSK, GSK.L) said Japan's Ministry of Health, Labour and Welfare has approved Arexvy for the prevention of respiratory ...
(Alliance News) - GSK PLC on Monday said the Japan Ministry of Health, Labour & Welfare has approved Arexvy for adults over 60. Arexvy is a vaccine used for the prevention of respiratory syncytial ...
